Disease · EFO_0801084
cancer pain
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. cancer pain. Diseases, record EFO_0801084. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0801084
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- cancer pain
- Open Targets ID
- EFO_0801084
- Other names
- cancer-associated pain, cancer-related pain
- Highest stage of its drugs
- Approval, for 2 of its 43 drugs, from TTD
Source Open Targets
Drugs43
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SAMARIUM SM 153 LEXIDRONAM PENTASODIUM | CHEMBL2096660 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| STRONTIUM CHLORIDE SR 89 | CHEMBL1200625 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| MORPHINE | CHEMBL70 | Small molecule | Phase 3 | ClinicalTrials.gov | 15 | 15 | 15 | Drugs and targets |
| FENTANYL | CHEMBL596 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 14 | 13 | 13 | Drugs and targets |
| HYDROMORPHONE | CHEMBL398707 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| METHADONE | CHEMBL651 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| OXYCODONE | CHEMBL656 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| DRONABINOL | CHEMBL465 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 3 | Drugs and targets |
| KETAMINE | CHEMBL742 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| CANNABIDIOL | CHEMBL190461 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 3 | Drugs and targets |
1 to 10 of 43
See all 43 drugsTargets47
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| OPRM1 | Mu-type opioid receptor | 16 | Mu opioid receptor agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| OPRK1 | Kappa-type opioid receptor | 4 | Kappa opioid receptor agonist; Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4986 | Drugs and targets |
| OPRD1 | Opioid receptors; mu/kappa/delta | 3 | Opioid receptors; mu/kappa/delta agonist; Opioid receptors; mu/kappa/delta antagonist | Phase 3 | https://conductscience.org/library/genes/4985 | Drugs and targets |
| CNR1 | Cannabinoid receptor 1 | 2 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| GRIN1 | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2902 | Drugs and targets |
| GRIN2A | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2903 | Drugs and targets |
| GRIN2B | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2904 | Drugs and targets |
| GRIN2C | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2905 | Drugs and targets |
| GRIN2D | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2906 | Drugs and targets |
| GRIN3A | Glutamate [NMDA] receptor | 2 | Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/116443 | Drugs and targets |
1 to 10 of 47
See all 47 targetsTrials79
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01337089 | Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain | Phase 3 | 660 | 2018-04-23 | Pain, Advanced Cancer | NABIXIMOLS | Its record names the disease | ClinicalTrials.gov |
| NCT01165281 | A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain | Phase 3 | 343 | 2014-01-15 | Pain | OXYCODONE, TAPENTADOL | Its record names the disease | ClinicalTrials.gov |
| NCT01205126 | An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain | Phase 3 | 260 | 2013-11-25 | Pain | HYDROMORPHONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01675622 | Immediate-Release Oxycodone Capsules Study in Cancer Pain | Phase 3 | 242 | 2018-05-21 | Cancer | MORPHINE, OXYCODONE | Its record names the disease | ClinicalTrials.gov |
| NCT01885182 | Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain | Phase 3 | 232 | 2019-09-16 | Cancer, Pain | OXYCODONE | Its record names the disease | ClinicalTrials.gov |
| NCT01964378 | CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer | Phase 3 | 200 | 2019-12-30 | Pain, Neoplasms, Chronic Pain | CEBRANOPADOL, MORPHINE SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT00674609 | A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy | Phase 3 | 177 | 2012-08-13 | Palliative Care, Pain, Cancer | CANNABIDIOL, DRONABINOL | Its record names the disease | ClinicalTrials.gov |
| NCT00644787 | A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain | Phase 2/3 | 156 | 2013-05-21 | Pain, Cancer | FENTANYL | Its record names the disease | ClinicalTrials.gov |
| NCT02609828 | Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy | Phase 3 | 156 | 2023-01-20 | Bone Metastasis, Cancer Pain | TANEZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01309386 | A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants | Phase 3 | 100 | 2013-03-13 | Neoplasms | MORPHINE, TAPENTADOL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 79
See all 79 trialsComparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tapentadol (JNS024) Extended-release (ER) Oral Tablets vs Oxycodone Controlled-release (CR) Oral Tablets: serious adverse events | 78 of 168 | 69 of 172 | 340 | NCT01165281 | Trial comparisons |
| Hydromorphone Hydrochloride (HCl) vs Oxycodone HCl Controlled Release (CR): serious adverse events | 11 of 128 | 18 of 126 | 254 | NCT01205126 | Trial comparisons |
| Oxycodone Capsules for Cancer Pain vs Morphine Tablets for Cancer Pain: deaths from any cause | 2 of 120 | 2 of 118 | 238 | NCT01675622 | Trial comparisons |
| Oxycodone Capsules for Cancer Pain vs Morphine Tablets for Cancer Pain: serious adverse events | 4 of 120 | 2 of 118 | 238 | NCT01675622 | Trial comparisons |
| Oxycodone/Naloxone vs Oxycodone: deaths from any cause | 8 of 114 | 4 of 111 | 225 | NCT01885182 | Trial comparisons |
| Oxycodone/Naloxone vs Oxycodone: serious adverse events | 14 of 114 | 12 of 111 | 225 | NCT01885182 | Trial comparisons |
| Cebranopadol vs Morphine Prolonged Release: deaths from any cause | 3 of 66 | 5 of 66 | 132 | NCT01964378 | Trial comparisons |
| Cebranopadol vs Morphine Prolonged Release: serious adverse events | 14 of 65 | 11 of 61 | 126 | NCT01964378 | Trial comparisons |
| Tapentadol ER vs Morphine SR: Number of Participants Who Discontinued Study Treatment Due to Lack of Efficacy | 3 of 50 | 1 of 50 | 100 | NCT01309386 | Trial comparisons |
| Tapentadol ER vs Morphine SR: serious adverse events | 16 of 50 | 16 of 50 | 100 | NCT01309386 | Trial comparisons |
1 to 10 of 17
See all 17 comparisons in its trialsPapers from its trials46
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0801084
GET https://conductscience.org/api/diseases/v1/EFO_0801084/drugs?page=2